Blood Res 2016; 51(4): 242-248
Therapy-related myeloid neoplasms in children and adolescents
Hee Won Cho1, Young Bae Choi2, Eun Sang Yi1, Ji Won Lee1, Ki Woong Sung1, Hong Hoe Koo1, Keon Hee Yoo1,3
Department of Pediatrics, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, 2Chung-Ang University Hospital, 3Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Korea
Correspondence to: Keon Hee Yoo, M.D., Ph.D.
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Received: May 17, 2016; Revised: August 18, 2016; Accepted: September 6, 2016; Published online: December 31, 2016.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This retrospective study aimed to characterize and analyze the outcome of therapy-related myeloid neoplasms (t-MNs) in children and adolescents.
The medical records of 16 patients under 21 years of age at the time of t-MN diagnosis were reviewed.
The median patient age was 11.5 years (range, 1.6‒20.4 yr). Twelve patients had therapy-related acute myeloid leukemia, 3 patients had myelodysplastic syndrome, and 1 patient had chronic myelomonocytic leukemia. The median latency period was 29 months (range, 11‒68 mo). Fourteen patients had cytogenetic aberrations, 8 of whom had an 11q23 abnormality. Of the 13 patients treated with curative intent, 12 patients received myeloid-type induction therapy that led to complete remission (CR) in 8 patients. Nine patients underwent allogeneic transplantation; 4 patients did not undergo transplantation due to chemotherapy-related toxic death (N=3) or parental refusal (N=1). The 5-year overall survival and event-free survival of the 13 patients treated with a curative intent were 46.2% and 30.8%, respectively. For the 9 patients who underwent allogeneic transplantation, the 5-year event-free survival was 66.7%.
A significant proportion of young patients with t-MNs can experience long-term survival, and allogeneic transplantation plays a key role for attaining cure in these patients.
Keywords: Therapy-related myeloid neoplasms, Pediatric population, Allogeneic hematopoietic stem cell transplantation

Current Issue


Indexed/Covered by